Sylvia Wolsky
Family · Anderson, SCNPI 1104473065
Payments from drug & device makers
Across 217 payments — averaging $16.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Harmony Biosciences LLC$498
- GSK$436
- Grifols USA, LLC$417
- Takeda Pharmaceuticals U.S.A., Inc.$403
- AstraZeneca$285
- Boehringer Ingelheim$220
- plus $1K from 19 others
What the payments were for
- Food & beverage$3,556100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Harmony Biosciences LLC | 41 | $498 |
| GSK | 30 | $436 |
| Grifols USA, LLC | 25 | $417 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $403 |
| AstraZeneca | 17 | $285 |
| Boehringer Ingelheim | 12 | $220 |
| Idorsia Pharmaceuticals US Inc | 10 | $194 |
| Electromed, Inc. | 17 | $190 |
| Regeneron Healthcare Solutions, Inc. | 9 | $170 |
| Mylan Specialty L.p. | 5 | $112 |
| Galderma Laboratories, L.p. | 3 | $86 |
| Actelion Pharmaceuticals US, Inc. | 4 | $68 |
| Insmed, Inc. | 3 | $61 |
| Lilly USA, LLC | 2 | $55 |
| Axsome Therapeutics, Inc. | 2 | $52 |
| Sanofi | 3 | $50 |
| Philips North America LLC | 2 | $45 |
| Mallinckrodt Hospital Products Inc. | 3 | $45 |
| Amgen | 2 | $42 |
| Merck | 2 | $41 |
| Genentech USA, Inc. | 1 | $21 |
| Baxter Healthcare | 1 | $20 |
| United Therapeutics Corporation | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $11 |
How this compares
$3,556 in reported general payments places this provider in the 85th percentile of 3,248 family providers in South Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $30,073 |
| BelsomraSuvorexant | 11 | $4,708 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 36 | $737 |
| Montelukast Sodium | 37 | $399 |
| ProgesteroneProgesterone, Micronized | 16 | $390 |
| Clonazepam | 11 | $197 |
| Zolpidem Tartrate | 11 | $31 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $436 | $30,07337 claims |
| MerckBelsomra | $41 | $4,70811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,248 family providers in South Carolina.
Other family in Anderson
- Kara Cooper GilmerAnderson$127K
- Nancy RichmondAnderson$21K
- Margaret KelleyAnderson$12K
- Lisa CobbAnderson$11K
- Sarah HambyAnderson$10K
- Alison FogartyGreenville$2M
- Sara ChristieGreenville$229K
- Jessica BellEasley$96K
- Carrie HendersonGreenville$91K
- Sarah ValerioGreer$76K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.